GTHP Stock UPDATES Guided Therapeutics (GTHP) 0.3900 09/02/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Guided Therapeutics (GTHP) 0.3900 $GTHP

Guided Therapeutics Initiates Cervical Cancer Screening Trial for LuViva(R) Advanced Cervical Scan
Business Wire - Tue Aug 19, 7:02AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it will begin enrollment this week in a multi-center clinical trial to expand claims for the LuViva(R) Advanced Cervical Scan to include front-line screening for cervical cancer.

Guided Therapeutics Reports Second Quarter 2014 Results
Business Wire - Wed Aug 13, 3:07PM CDT
--Submitted amended PMA for LuViva(R) Advanced Cervical Scan

Guided Therapeutics to Report Second Quarter 2014 Results and Hold Conference Call
Business Wire - Thu Jul 31, 2:11PM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its second quarter ended June 30, 2014 on Wednesday, August 13, 2014, after the market closes.

Guided Therapeutics Files PMA Amendment with FDA for LuViva(R) Advanced Cervical Scan
Business Wire - Fri Jul 25, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has filed an amendment to its premarket approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the LuViva(R) Advanced Cervical Scan.

Guided Therapeutics Granted Additional Key Patent for LuViva(R) Advanced Cervical Scan
Business Wire - Thu Jul 17, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that U.S. Patent and Trademark Office granted a new patent with 22 claims that support the technology behind the LuViva(R) Advanced Cervical Scan.

Guided Therapeutics' LuViva(R) Advanced Cervical Scan Awarded Mexican Regulatory Approval
Business Wire - Thu Jul 10, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that LuViva(R) Advanced Cervical Scan was approved for sale in Mexico by the Federal Commission for Protection against Health Risks (COFEPRIS).

Guided Therapeutics Second Quarter Sales to Reach $200,000; Update Timing for Amended PMA Application for LuViva(R) Advanced Cervical Scan
Business Wire - Wed Jul 02, 12:22PM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today provided anticipated sales results for its second quarter ended June 30, 2014 and also provided updated timing regarding the submittal of its amendment to its premarket approval (PMA) application for the LuViva(R) Advanced Cervical Scan.

Gene S. Cartwright of Guided Therapeutics, Inc (GTHP)-OTC bought Shares of GTHP
M2 - Thu Jun 19, 9:40AM CDT
Reported by InsiderCow.com at 2014-06-18 19:03:00 ET

Guided Therapeutics' LuViva(R) Advanced Cervical Scan Wins Prestigious Medical Design Award
Business Wire - Thu Jun 12, 7:01AM CDT
The LuViva(R) Advanced Cervical Scan was chosen as best designed new medical device of 2014 at the 17th Annual Medical Device Excellence Awards (MDEA) ceremony held Wednesday, June 11, 2014, in conjunction with the MD&M East event at the Jacob K. Javits Convention Center in New York. LuViva, a newly introduced product for the early detection of disease that leads to cervical cancer, is manufactured and sold by Guided Therapeutics, Inc. (OTCBB:GTHP) (OTCQB:GTHP).

Guided Therapeutics Submits Request for Face to Face Meeting with FDA; Receives Notification on PMA Extension for LuViva(R) Advanced Cervical Scan
Business Wire - Thu Mar 27, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company has submitted a letter requesting a face-to-face meeting with the U.S. Food and Drug Administration (FDA) in the next 60 to 90 days. This letter is in response to the September 6, 2013 letter that the company received from the FDA. Additionally, the FDA has granted the company its requested 180 day extension on the PMA filing to allow time for the meeting to occur.

Guided Therapeutics Reports Fourth Quarter and 2013 Results
Business Wire - Wed Mar 26, 3:44PM CDT
--LuViva(R) Advanced Cervical Scan momentum building with key opinion leaders; increasing number of product evaluations

HPV Screening Beneficial for Guided Therapeutics' LuViva(R) Advanced Cervical Scan in Developed Countries; No Anticipated Impact in Developing Countries
Business Wire - Tue Mar 18, 7:05AM CDT
The March 12, 2014, recommendation by a U.S. Food and Drug Administration (FDA) panel to use human papillomavirus (HPV) testing as an alternative to Pap testing for screening of women for cervical cancer has the potential to increase the need for the LuViva(R) Advanced Cervical Scan in developed countries, according to Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP). As part of its CE Mark, LuViva is already approved for use in the European Union as a triage test to be used after a positive HPV test and/or a positive Pap test.

Guided Therapeutics to Report Fourth Quarter 2013 Results and Hold Conference Call
Business Wire - Wed Mar 05, 2:40PM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its fourth quarter ended December 31, 2013 on Wednesday, March 26, 2014, after the market closes.

New Clinical Study Results of Guided Therapeutics' LuViva(R) Advanced Cervical Scan to be Presented by Key Opinion Leaders at Top International Medical Conference
Business Wire - Tue Feb 18, 7:05AM CST
The Secretary General of the International Federation for Cervical Pathology and Colposcopy (IFCPC), Dr. James Bentley, will present results of a new clinical study of the LuViva(R) Advanced Cervical Scan at the 15th World Congress for Cervical Pathology and Colposcopy, being held May 26 - 30 in London. The LuViva, a non-invasive device used to detect cervical disease instantly at the point of care, is a product of Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP).

2014 Analysis of the US Hospital Cancer Diagnostics Market
M2 - Thu Feb 13, 3:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/g5hk8t/2014_analysis_of) has announced the addition of the "2014 Analysis of the US Hospital Cancer Diagnostics Market" report to their offering. This new report contains 533 pages, 43 tables, and presents a comprehensive analysis of the US hospital cancer diagnostics market, including: - Major issues pertaining to the French hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. - Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. - Test volume and sales forecasts for 40 cancer diagnostic procedures performed in French hospitals. - Current instrumentation technologies and feature comparison of leading analyzers. - Sales and market shares of leading suppliers. - Emerging diagnostic technologies and their potential market applications. - Product development opportunities. - Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. - Business opportunities and strategic recommendations for suppliers. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And Market Needs D. Current and Emerging Technologies US A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Growth and Major Suppliers Major Product Development Opportunities A. Reagent Kits and Test Systems/Panels B. Instrumentation C. Computers, Software and Automation D. Auxiliary Products Design Criteria for Decentralized Testing Products Alternative Market Penetration Strategies A. Internal Development B. Collaborative Arrangements C. University Contracts D. Distribution Strategies 1. Marketing Approaches 2. Product Complexity 3. Customer Preference 4. Established Suppliers 5. Emerging Suppliers 6. Major Types of Distributors 7. Market Segmentation Factor Potential Market Entry Barriers and Risks A. Market Maturity B. Cost Containment C. Competition D. Technological Edge and Limitations E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges Companies Mentioned: - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/g5...nalysis_of

2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities
M2 - Mon Feb 10, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/r66j8d/2014_analysis_of) has announced the addition of the "2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities" report to their offering. This new report contains 1,200 pages, 450 tables and provides forecasts for 40 tumor markers by country and market segment, as well as sales and market shares for reagent and instrument suppliers. The report is available by region, country, section, market segment and individual test: Regions: Global, Europe Countries: France, Germany, Italy, Japan, Spain, UK, USA Sections: Assays, Competitors, Instrumentation, Technologies Market Segments: Hospitals (France, Germany, Italy, Japan, Spain, UK, USA), Personalized Testing Tests: AFP, Beta-2 Microglobulin,CA Tumor Markers, CEA, Cell Surface Markers, Occult Blood, PAP, Pap Smear/HPV, PSA To purchase a DataPack that includes (test volumes, sales forecasts, supplier shares) please E-mail us. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And D. Current and Emerging Technologies Competitive Profiles - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - Biomedical Diagnostics - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila - bioMerieux For more information visit http://www.researchandmarkets.com/research/r6...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Niko Receives Conversion Notice
Marketwire - Thu Jan 09, 5:01PM CST
Niko Resources Ltd. (TSX: NKO) announces that on January 8, 2014, it received a notice of conversion in accordance with the terms of the amended and restated 7% senior unsecured notes due July 13, 2014 (the "Notes" to convert approximately US$0.25 million of the Notes. The conversion will result in the issuance of 120,904 common shares to a holder of the Notes and the outstanding principal balance of the Notes will be approximately US$8.3 million.

Guided Therapeutics Names Gene Cartwright as Chief Executive Officer
Business Wire - Tue Jan 07, 7:04AM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), the maker of the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly at the point of care, today announced the appointment of Gene Cartwright, 59, as Chief Executive Officer, effective January 6, 2014. Mr. Cartwright replaces Mark L. Faupel, who has transitioned to the role of Chief Scientific Officer.

Global Point of Care (PoC) Diagnostic Testing: World Market Report 2013
M2 - Tue Dec 17, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/b8xvhg/point_of_care) has announced the addition of the "Global Point of Care (PoC) Diagnostic Testing: World Market Report 2013" report to their offering. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening. "Global Point of Care (PoC) Diagnostic Testing: World Market Report 2013", describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections both in the U.S. and worldwide - including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Companies Mentioned: - Axxin - Biosensia Ltd - Curetis AG - DxNA, LLC - Exalenz Bioscience - Guided Therapeutics, Inc - Home Diagnostics - International Technidyne Corporation - Johnson & Johnson - LifeSign, LLC - Mitsubishi Kagaku Iatron - Nova Biomedical - Orion Diagnostica - Prima Biomedical Company - Quidel Corporation - Roche Diagnostics - Strategic Diagnostics - Trinity Biotech, Plc - Venaxis, Inc - Wave 80 Biosciences For more information visit http://www.researchandmarkets.com/research/b8...nt_of_care

Guided Therapeutics Receives Additional Questions from FDA for LuViva(R) Advanced Cervical Scan
Business Wire - Mon Sep 09, 6:00AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company received additional questions from the U.S. Food and Drug Administration (FDA) regarding the pre-market approval application for the LuViva(R) Advanced Cervical Scan. FDA advised the company the PMA was not yet approvable in its current form and that the company needed to address these questions in order to place the PMA in approvable form.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 126

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 139

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 78

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 75

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 88

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 81

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 44

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 107

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 86

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 147

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading

Top 5 Most Recently Viewed Articles

Eimskip's Q3 2025 Financial Overview and Future Outlook

Updated Category News Views 238

Eimskip's Third Quarter Performance Analysis The results for the third quarter of 2025 have presented challenges for Eimskip, as operations did not meet expectations. Revenues showed significant shifts, revealing both obstacles and opportunities in the company's journey. Operational Insights During Q3, Eimskip experienced a slight increase in liner shipping volumes,...

Continue Reading
Market Trends and Insights: The Bullish Moves on Block

Updated Category News Views 88

Examining Recent Bullish Moves on Block Recently, financial institutions have been making significant bullish strides into Block, a company known for its innovative payment services. Analysis of the options trading history for Block (NASDAQ: SQ) indicates a noticeable interest, with 16 unusual trades captured, providing insights into market direction and trader sentiment....

Continue Reading
Exploring the Soaring Online Poker Market Growth Trends

Updated Category News Views 157

Online Poker Market: A Surge on the Horizon The Global Online Poker Market is currently undergoing a transformative expansion, predicted to rise from USD 7.98 billion in 2024 to an impressive USD 37.19 billion by 2030. This notable growth reflects a compound annual growth rate (CAGR) of 29.24%, driven by advancements in technology such as enhanced smartphone capabilities,...

Continue Reading
Elevate Your Gaming with Jackbit's New Crypto Welcome Offer

Updated Category News Views 182

Jackbit’s New Welcome Bonus for Crypto Players As online gaming evolves, Jackbit Crypto Casino is launching an exciting new welcome bonus tailored specifically for cryptocurrency enthusiasts. Starting next year, all new players joining the Jackbit platform will enjoy the same welcome bonuses that traditional fiat customers have been taking advantage of. This bold move...

Continue Reading
Eli Lilly's Mounjaro Drug Set to Revolutionize Weight Loss in Hong Kong

Updated Category News Views 214

Eli Lilly to Launch Weight Loss Drug Mounjaro in Hong Kong Eli Lilly & Co. (NYSE: LLY) is poised to launch its well-regarded weight-loss medication, Mounjaro, in Hong Kong shortly. This marks an exciting milestone, as it positions Mounjaro to be the first of its kind available in the broader region of China. The anticipated launch follows recent reports indicating that...

Continue Reading